New trial
Phase 1 study of STM-416p, a resiquimod TLR7/8 activator
- Trial ID
- NCT06450106 on ClinicalTrials.gov
- Cancer type
- Prostate Cancer
- Stage of research
- First-in-human
- Location
- 2 Locations
- Published in
- New in Oncology - June 23, 2025
This study evaluates the safety and optimal dosing of intraoperative STM-416p in men with Grade group 2–5 prostate cancer undergoing radical prostatectomy. Conducted at Tucson and Gainesville sites, the trial is sponsored by SURGE Therapeutics and represents a novel application of a resiquimod TLR7/8 activator for localized cancer treatment.
More in prostate cancer
-
Trial result · Oct 22, 2026 · NCT03732820
Olaparib (PARP inhibitor) + Abiraterone (CYP17 AR-pathway inhibitor) Extends rPFS in Non‑BRCA mCRPC (PROpel) -
New trial · Oct 15, 2026 · NCT07813637
Phase 1 JANX013 PSMA×CD28 costimulation combines with JANX007 PSMA×CD3 T-cell engagement -
New trial · Oct 15, 2026 · NCT07832292
Phase 2 JNJ-101556143 uses an AR-BRD4 induced-proximity mechanism in resistant prostate cancer -
New trial · Oct 8, 2026 · NCT07824349
Phase 1a/1b JUR-003 KLK2×CD3 bispecific T‑cell engager in metastatic prostate cancer -
New trial · Oct 1, 2026 · NCT07803653
Phase 1 FH-STEAP1 IL-18 CAR T tests STEAP1-targeted CAR-T armored with IL-18